ProCE Banner Activity


Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer

Text Module

Read this text module to learn about emerging therapies targeting DLL3 for the treatment of small-cell lung cancer.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 12, 2023

Expiration: April 11, 2024



Hossein Borghaei

Hossein Borghaei, MS, DO

Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


This activity is supported by educational funding provided by


Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who care for patients with SCLC.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in understanding the latest science, emerging conference and clinical trial data, and ongoing clinical trials in DLL3-targeting therapies in SCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the mechanism of action of DLL3-targeting therapies and the biologic rationale for their investigation in SCLC to colleagues, patients, and caregivers

  • Evaluate ongoing clinical trial research investigating novel agents and treatment strategies that incorporate DLL3-targeting therapies for patients with SCLC

  • Identify patients for clinical trials investigating DLL3-targeting agents in SCLC and other tumors


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Hossein Borghaei, MS, DO

Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Hossein Borghaei, DO, MS: researcher: Amgen, Bristol-Myers Squibb, Lilly; consultant/advisor/speaker: Amgen, AstraZeneca, Axiom, Beigene, Boehringer Ingelheim, Bristol-Myers Squibb, BioNTech, Daiichi Sankyo, Da Volterra, EMD-Serono, Genentech, Genmab, Guardant, iTEO, Janssen, Jazz, Lilly, Merck, Mirati, Natera, Novartis, Oncocyte, Pfizer, PharmaMar, Puma, Regeneron, Takeda; data and safety monitoring board: Incyte, Novartis, Springworks, Takeda; stock options: Inspirna, Nucleai, Sonnetbio.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 12, 2023, through April 11, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.